Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations (2016 - 2026)

Anika Therapeutics has reported Income from Continuing Operations over the past 17 years, most recently at 5056000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 27.39% to 5056000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 839000.0 through Mar 2026, up 93.11% year-over-year, with the annual reading at 268000.0 for FY2025, 102.64% up from the prior year.
  • Income from Continuing Operations was 5056000.0 for Q1 2026 at Anika Therapeutics, down from 12039000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 17100000.0 in Q4 2023 and troughed at 10350000.0 in Q1 2023.
  • The 5-year median for Income from Continuing Operations is 2933000.0 (2022), against an average of 1258647.06.
  • Year-over-year, Income from Continuing Operations plummeted 845.88% in 2022 and then surged 416.82% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 6080000.0 in 2022, then skyrocketed by 181.25% to 17100000.0 in 2023, then plummeted by 122.22% to 3800000.0 in 2024, then surged by 416.82% to 12039000.0 in 2025, then plummeted by 142.0% to 5056000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Income from Continuing Operations are 5056000.0 (Q1 2026), 12039000.0 (Q4 2025), and 3175000.0 (Q3 2025).